Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Modified mosquitoes to fight Zika and dengue fever
Aedes mosquito
The Eliminate Dengue Programme has pioneered a way to transfer Wolbachia into Aedes aegypti mosquitoes.

Researchers hope to significantly reduce new cases

Scientists are set to deploy millions of modified mosquitoes in Brazil and Columbia to combat Zika and other mosquito-borne viruses.


Supported by the UK Government, USAID, Wellcome and The Bill & Melinda Gates Foundation, the innovative control method will use naturally occurring Wolbachia bacteria.


Found in up to 60 per cent of all insect species, research shows that Wolbachia can significantly reduce the capacity of mosquitoes to pass viruses to humans. But Wolbachia does not occur naturally in Aedes aegypti - the mosquito species primarily responsible for transmitting diseases like Zika and dengue fever.


Established in 2011, The Eliminate Dengue Program (EDP) has pioneered a way to transfer Wolbachia into Aedes aegypti mosquitoes. Years of research show that Wolbachia makes this species of mosquito incapable of transmitting viruses.


Scientists say when mosquitoes with Wolbachia are released into an area, they breed with local mosquitoes and pass the bacteria to their offspring. Within a few months, the majority of mosquitoes carry Wolbachia and this effect is then self-sustaining without the need for further releases.


The EDP has been conducting Wolbachia field trials in Indonesia, Australia and Vietnam for several years. In 2014, the team initiated small-scale field trials in Rio de Janeiro, Brazil and Bello, followed by Colombia in 2015.


Funding announced on Monday (26 October) will finance the rapid scale-up of Wolbachia deployments in Latin America, commencing early 2017. Wolbachia coverage will then extend across Bello and other parts of Antioquia and parts of the greater Rio de Janeiro area.


“Wolbachia could be a revolutionary form of protection against mosquito-borne disease. It’s affordable, sustainable, and appears to provide protection against Zika, dengue, and a host of other viruses,” explained Dr Trevor Mundel, president of the Global Health Division of the Bill & Melinda Gates Foundation. “We’re eager to study its impact and how it can help countries.”


Professor Scott O’Neill, EDP's programme leader added: “We are incredibly grateful to our funding partners for enabling us to expand this research across two large urban areas vulnerable to mosquito - transmitted disease.


“The Gates Foundation and Wellcome have supported our work since 2005 and their ongoing commitment, along with new donors, to reducing the spread of mosquito-borne viruses is pivotal to us moving from small scale trials to large city-wide deployment.”

Over the next two to three years, planned deployments will scientifically measure the impact of the intervention on disease transmission in large, urban settings.

Researchers hope to show a significant reduction in new cases of Zika, dengue and chikungunya.


Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.